Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

Author： Seystahl Katharina   Weller Michael  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.5, 2012-05, pp. : 605-617

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

By Tomao Federica   Papa Anselmo   Rossi Luigi   Caruso Davide   Zoratto Federica   Benedetti Panici Pierluigi   Tomao Silverio  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 37-53

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab ± irinotecan beneficial for glioblastoma

By  

Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Bevacizumab: In Previously Treated Glioblastoma

By Moen Marit D.  

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 181-189

Adis International

Access to resources Recommend Favorite

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

By Jakobsen Jan Nyrop   Hasselbalch Benedikte   Stockhausen Marie-Thééréése   Lassen Ulrik   Poulsen Hans Skovgaard  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 825-833

Informa Healthcare

Access to resources Recommend Favorite

Targeting the AKT Pathway in Glioblastoma

By  

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2411-2420

Bentham Science Publishers

Access to resources Recommend Favorite